Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Whole genome-based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.

In 27 people with urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab, 22 of whom had muscle-invasive bladder cancer, Next Personal Dx ctDNA clearance occurred in 11 of the evaluable patients and was described as tracking with clinical and radiographic response.

ASCO Genitourinary Cancers Symposium 2026